The U.S. Food and Drug Administration (FDA) is limiting the use of Johnson & Johnson’s (JNJ)
COVID-19 vaccine for adults due to the risk of blood clots.
The Johnson & Johnson vaccine is authorized for use in people aged 18 and older and is one of
the three COVID-19 vaccines cleared for use in the U.S., along with shots from Pfizer (PFE) and
Moderna (MRNA).
However, the FDA said that its analysis had determined that the risk of thrombosis with
thrombocytopenia syndrome (a rare blood clot disorder) after the administration of the vaccine
warrants limiting its use in the adult population.
The FDA added though that Johnson & Johnson’s vaccine can still be administered in cases
where authorized or approved COVID-19 vaccines are not readily accessible, or if an individual
is less keen on using the other two available vaccines.
Johnson & Johnson’s stock is up 3% year to date at $176.76 U.S. a share.
Related Stories
